- Home
- HROW vs OLMA Comparison
HROW vs OLMA Comparison
Compare HROW & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HROW | OLMA |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HROW | OLMA |
|---|---|---|
| Price | $34.10 | $14.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $71.14 | $41.13 |
| AVG Volume (30 Days) | 924.6K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.68 | N/A |
| Revenue Next Year | $40.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.85 | $2.86 |
| 52 Week High | $54.98 | $36.26 |
Technical Indicators
Market Signals| Indicator | HROW | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 27.80 | 20.04 |
| Support Level | $30.55 | $4.35 |
| Resistance Level | $40.64 | $27.38 |
| Average True Range (ATR) | 2.54 | 1.35 |
| MACD | -1.45 | -0.94 |
| Stochastic Oscillator | 2.31 | 3.20 |
Price Performance
Historical ComparisonAbout HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.